McGuire Investment Group LLC raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating ) by 2.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,473 shares of the company’s stock after purchasing an additional 1,386 shares during the period. Medpace makes up 1.9% of McGuire Investment Group LLC’s portfolio, making the stock its 21st biggest position. McGuire Investment Group LLC’s holdings in Medpace were worth $10,220,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Yarbrough Capital LLC boosted its holdings in Medpace by 80.7% in the first quarter. Yarbrough Capital LLC now owns 4,472 shares of the company’s stock valued at $732,000 after purchasing an additional 1,997 shares in the last quarter. Cim LLC boosted its holdings in Medpace by 2.8% in the first quarter. Cim LLC now owns 2,570 shares of the company’s stock valued at $409,000 after buying an additional 69 shares in the last quarter. Front Row Advisors LLC boosted its stake in Medpace by 3.9% in the 4th quarter. Front Row Advisors LLC now owns 10,809 shares of the company’s stock valued at $2,352,000 after acquiring an additional 409 shares in the last quarter. Green Square Capital Advisors LLC purchased a new position in Medpace during the 4th quarter valued at $218,000. Finally, Castleark Management LLC purchased a new position in Medpace during the 4th quarter valued at $9,694,000. 79.70% of the shares are owned by institutional investors and hedge funds.
Shares of Medpace stock opened at $156.70 on Wednesday. The firm’s 50-day moving average is $140.63 and its 200-day moving average is $159.32. Medpace Holdings, Inc. has a 1-year low of $126.94 and a 1-year high of $231.00. The company has a market cap of $5.27 billion, a P/E ratio of 29.24 and a beta of 1.43.
Medpace (NASDAQ:MEDP – Get Rating ) last posted its quarterly earnings results on Monday, April 25th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.43. Medpace had a net margin of 16.47% and a return on equity of 24.17%. The company had revenue of $330.90 million for the quarter, compared to the consensus estimate of $327.09 million. During the same period last year, the firm posted $1.17 EPS. The company’s revenue for the quarter was up 27.3% on a year-over-year basis. As a group, stock analysts expect Medpace Holdings, Inc. to post 5.87 EPS for the current year.
MEDP has been the subject of a number of analyst reports. StockNews.com initiated coverage on shares of Medpace in a research note on Thursday, March 31st. They assign a “buy” rating to the stock. Guggenheim initiated coverage on shares of Medpace in a research note on Monday, May 23rd. They assign a “neutral” rating to the stock. Finally, Robert W. Baird boosted their price objective on shares of Medpace from $160.00 to $175.00 in a research note on Thursday, March 17th.
About Medpace (Get Rating)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe and Asia. It offers a range of services supporting the clinical development process from phase I to phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology and medical industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, new drug submissions for pharmacovigilance, and post-marketing clinical support services.
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating).
Get Medpace Daily news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medpace and related companies with MarketBeat.com ‘s FREE daily email newsletter.